Johnson and Johnson 2008 Annual Report Download - page 27

Download and view the complete annual report

Please find page 27 of the 2008 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 76

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76

Y E A R I N R E V I E W 25
A New Era
in Diagnostics
Vision Care Franchise
Continues to Grow
The Ortho-Clinical Diagnostics, Inc. (OCD)
fully integrated, global business comprises
laboratory tests and instrumentation
for use in transfusion medicine and clinical
laboratories. OCD is driving growth in its
core businesses with new products
and launching high-impact medical tests in
molecular and cellular diagnostics that
will create an entirely new type of value for
the medical system.
In 2008, the company brought to market
two new laboratory systems: the VITROS®
5600 Integrated System and the VITROS®
3600 Immunodiagnostic System. These
next-generation instruments are designed
to run more than 100 clinical chemistry and
immunoassay tests.
OCD hasa strongpipelinethatissupported
by recent investments, including a new state-
of-the-art manufacturing plant in Pencoed,
Wales, and an acquisition securing a point-of-
care channel that will allow the company to
bring diagnostics directly to the physician.
Diagnostics play a major role in health
care outcomes: More than 60 percent
of health care decisions are made using
diagnostic test results. Matching diagnostics
with therapies allows for a more targeted
approach,providinginformationthatphysicians
can use to improve patient outcomes.
Diagnostics can help Johnson & Johnson
achieve organic convergence, leveraging its
broad-based position in health care
to drive new approaches in patient care. OCD
is committed to bringing products to market
that can identify illnesses in advance of
disease, potentially avoiding progression to
more serious disorders.
Johnson & Johnson Vision Care, Inc.
continues to maintain its leadership
position, launching numerous innovative
eye care products designed to improve the
lives of patients everywhere.
ACUVUE®remains the world’s most
widelyprescribedcontactlensbrand. In2008
the brand grew with the addition of two
new products: ACUVUE®OASYS™Brand
Contact Lenses for ASTIGMATISM and,
introduced in the United Kingdom, 1-DAY
ACUVUE®TruEye™, the world’s first daily
disposable silicone hydrogel contact lens.
Building on its partnership with eye care
practitioners,theVisionCare Institute™,LLC
nowhasmorethan11 sisterinstitutesin such
diverse cities as Bangkok, Shanghai, Tokyo,
Prague and Dubai. Launched in 2004 as a
source of continuous learning and
information, the Vision Care Institute™,
LLC and its sister units have trained more
than 30,000 eye practitioners worldwide.
ACUVUE®continues to be innovative in
other ways, such as using digital media with
tools like ACUMINDER™, a complimentary
online service (www.acuminder.com) that
sends an automatic reminder via e-mail,
text message or computer prompt to
change or order new contact lenses. The
expanded functionality of ACUMINDER™
Facebook (www.acuminder.com/facebook)
also allows users to send out reminders for
just about anything, such as taking daily
medications, doctors’ visits, work deadlines,
social events and more.
LARGEST MEDICAL DEVICE COMPANY IN THE WORLD
NO. 1 OR NO. 2 IN THE MAJORITY OF MARKETS IN WHICH WE COMPETE
WELL-POISED FOR GROWTH
Medical
Devices &
Diagnostics
Segment
Sales
Sales by
Major Franchise
(in billions of dollars)
2008 Sales:
$23.1 billion
Growth Rate: 6.4%
DEPUY®
$5.0
+9%
ORTHO-CLINICAL
DIAGNOSTICS®
$1.8
+8%
VISION CARE
$2.5
+13%
DIABETES
CARE
$2.5
+7%
ETHICON
ENDO-SURGERY®
$4.3
+12%
ETHICON®
$3.9
+7%
CORDIS®
$3.1
(9%)
*
* includes rounding